ProPhase Labs to Present at the 2025 ThinkEquity Conference
Rhea-AI Summary
ProPhase Labs (NASDAQ: PRPH) will participate in the ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental Hotel in New York.
Ted Karkus, CEO and Chairman, will present at 11:00 AM ET on October 30 and will hold one-on-one investor meetings throughout the day. Interested investors can register and schedule meetings via the provided registration link, and the presentation will be live-streamed at the supplied webcast URL.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PRPH gained 10.43%, reflecting a significant positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $16M at that time.
Data tracked by StockTitan Argus on the day of publication.
UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.
Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 11AM ET on October 30th. One-on-one investor meetings will be held throughout the day. Interested investors can register to attend and schedule one-on-one meetings here: https://www.meetmax.com/sched/event_121867/conference_home.html
The presentation will also be live-streamed at the following link:
https://event.summitcast.com/view/NX3WagbdCmRzBGMxdc3ia6/guest_book?session_id=PDgxE2V2WRZcL6RynfToZv
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com